NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies.
NeoTX Therapeutics was founded in 2015 by Asher Nathan. The company is headquartered in Rehovot, Israel.
NeoTX Therapeutics' STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.
NeoTX Therapeutics has raised $45M in a Series C round on Feb 19, 2020. This brings NeoTX's total funding to $60M to date.